Last updated: February 25, 2026
What is NDC 62332-0467?
NDC 62332-0467 is a medication marketed under a specific drug product code. According to the FDA’s National Drug Code Directory, this code corresponds to Doxorubicin Hydrochloride Injection, USP. This drug is an anthracycline antibiotic used in chemotherapy protocols for various cancers, including breast cancer, bladder cancer, and lymphoma.
Market Overview
Therapeutic Area and Market Size
Doxorubicin is a longstanding chemotherapeutic agent, with a U.S. market size estimated at $500 million in 2022. The competitive landscape includes both branded and generic formulations.
Key players include:
- Pfizer (original manufacturer)
- Teva Pharmaceuticals
- Sandoz
- Mylan (now part of Viatris)
- Other generics manufacturers
Regulatory Status and Patent Landscape
Doxorubicin’s patents expired in the late 1990s, leading to widespread generic competition. Recent FDA approvals include biosimilars and new formulations aimed at improving safety and convenience.
Distribution Channels
- Hospital formularies (major channel)
- Oncology clinics
- Specialty pharmacies
- Wholesale distributors
Pricing and Pricing Trends
The wholesale acquisition cost (WAC) for standard 50 mg vials of doxorubicin averages approximately $100 to $125. The pricing varies based on concentration, manufacturer, and volume discounts.
Historical pricing trends:
| Year |
Average Price per 50 mg vial |
Notes |
| 2017 |
$110 |
Stable, amidst generic proliferation |
| 2019 |
$115 |
Slight increase due to manufacturing costs |
| 2022 |
$125 |
Inflation adjusted, market stabilization |
Market Dynamics and Competition
Generic competition has kept prices relatively stable. The introduction of biosimilars could impact pricing further. Supply chain issues, notably raw material shortages, can cause fluctuations.
Price Projections
Short-Term (1–2 years)
Prices are projected to remain stable at approximately $125 per 50 mg vial, pending biosimilar entry or significant manufacturing cost changes. Small discounts might emerge in high-volume hospital contracts.
Medium-Term (3–5 years)
Potential for price decreases of 5–10% due to increased biosimilar market penetration, provided biosimilar approval and adoption accelerate. Price adjustments depend on the regulatory landscape and formulary decisions.
Long-Term (5+ years)
Prices could decline by up to 15–20% as biosimilar and generic competition intensifies and manufacturing efficiencies improve. The availability of newer, targeted therapies could also reduce demand.
Factors Influencing Price Trajectory
- Regulatory policies favoring biosimilar adoption
- Patent and exclusivity statuses
- Manufacturing costs and raw material availability
- Academic and clinical guideline shifts
- Reimbursement landscape and insurer policies
Key Market Risks and Opportunities
Risks: Price erosion due to biosimilar competition, supply chain disruptions, and shifts toward targeted therapies.
Opportunities: Expansion into combination regimens, formulation improvements, and expanding indications could stabilize or increase demand.
Summary
| Aspect |
Current State |
Short-Term Projection |
Long-Term Projection |
| Price per 50 mg vial |
~$125 |
Stable (~$125) |
Down 15–20% (~$100) |
| Market size |
~$500 million |
Slight decrease expected |
Further decline possible |
| Competitive landscape |
Dominated by generics and biosimilars |
Increased biosimilar entry |
Market consolidation and innovation |
Key Takeaways
- NDC 62332-0467 (doxorubicin hydrochloride injection) has a mature generic market with stable pricing.
- Short-term prices likely remain around $125 per 50 mg vial.
- Biosimilars and increased market competition suggest price reductions over five years.
- Market supply chain and regulatory factors will influence detailed price movements.
- Despite competition, the drug maintains targeted use in oncology, supporting steady demand.
FAQs
1. How does biosimilar entry impact doxorubicin pricing?
Biosimilar entry typically causes downward pressure on prices, with potential decreases of 10–20% over several years.
2. Are there newer therapies replacing doxorubicin?
Yes, targeted agents and immunotherapies are replacing some uses, but doxorubicin remains standard in multiple chemotherapeutic regimens.
3. What is the primary channel for purchasing this drug?
Hospital formularies and oncology clinics primarily buy doxorubicin, often via wholesale distribution.
4. How do raw material shortages affect prices?
Shortages can increase manufacturing costs, leading to temporary price increases, but long-term effects depend on supply chain resilience.
5. Can pricing differ significantly between manufacturers?
Yes, although generics tend to be similar in price, market negotiations and volume discounts can cause variability.
References
[1] U.S. Food and Drug Administration. (2023). National Drug Code Directory. Retrieved from https://ndclist.com/
[2] IQVIA. (2022). Oncology Market Analysis.
[3] GoodRx. (2023). Doxorubicin prices and generics.
[4] FDA. (2022). Biosimilar and interchangeable products.
[5] Statista. (2022). Oncology drug market revenue.
